People_

Dr Robin Gasiorowski

Dr Robin Gasiorowski completed medical training at Cambridge University and University College London, before moving to Australia in 2004. Following specialist haematology training at Royal Prince Alfred and Concord hospitals he now works as a clinical and laboratory haematologist, with appointments at Concord and Macquarie University Hospitals. He has a particular interest in acute leukaemia and high-grade lymphoma and in 2017 completed his PhD with the Dendritic Cell Research group at the University of Sydney, developing novel therapeutic antibodies for the treatment of Acute Myeloid Leukaemia (AML). Whilst he continues to be contribute to this group’s work, he also has a strong interest in clinical research, particularly in the development of novel immune therapies for patients with haematological malignancies. He has been a principal investigator on a number of industry and ALLG sponsored clinical trials for patients with high grade lymphoma and leukaemia.

Publications

By Type

Expand all

Journals

Thieblemont, C., Lewis, D., Kim, T., van der Poel, M., Poon, M., Feldman, T., Linton, K., Sureda, A., Hutchings, M., Dinh, M., Gasiorowski, R., et al (2024). Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. [More Information]
Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C., Clausen, M., Cunningham, D., Do, Y., Feldman, T., Gasiorowski, R., Jurczak, W., et al (2023). Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. Journal of Clinical Oncology, 41(12), 2238-2247. [More Information]
Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C., Clausen, M., Cunningham, D., Do, Y., Feldman, T., Gasiorowski, R., Jurczak, W., et al (2022). ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study. Clinical Lymphoma, Myeloma and Leukemia, 22, S379. [More Information]
Gasiorowski, R., Forbes, M., Silver, G., Krastev, Y., Hamdorf, B., Lewis, B., Tisbury, M., Cole-Sinclair, M., Lanphear, B., Klein, R., et al (2022). Effect of Plasma and Blood Donations on Levels of Perfluoroalkyl and Polyfluoroalkyl Substances in Firefighters in Australia: A Randomized Clinical Trial. JAMA Network Open, 5(4), E226257. [More Information]
Wong, J., Gruber, E., Maher, B., Waltham, M., Sabouri-Thompson, Z., Jong, I., Luong, Q., Levy, S., Kumar, B., Brasacchio, D., Gasiorowski, R., et al (2022). Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. Leukemia, 36(6), 1654-1665. [More Information]
Zinzani, P., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N., de Oliveira, J., Buccheri, V., Perini, G., Dickinson, M., et al (2022). Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Advances, 6(2), 590-599. [More Information]
Morschhauser, F., Feugier, P., Flinn, I., Gasiorowski, R., Greil, R., Illés, Á., Johnson, N., Larouche, J., Lugtenburg, P., Patti, C., et al (2021). A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood, 137(5), 600-609. [More Information]
Kuruvilla, J., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N., Fogliatto, L., Goncalves, I., de Oliveira, J., Buccheri, V., et al (2021). Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. The Lancet Oncology, 22(4), 512-524. [More Information]
Silver, G., Krastev, Y., Forbes, M., Hamdorf, B., Lewis, B., Tisbury, M., Taylor, M., Gasiorowski, R. (2021). Study protocol for a randomised controlled trial examining the effect of blood and plasma donation on serum perfluoroalkyl and polyfluoroalkyl substance (PFAS) levels in firefighters. BMJ Open, 11(5), e044833. [More Information]
Di Ciaccio, P., McCaughan, G., Trotman, J., Ho, P., Cheah, C., Gangatharan, S., Wight, J., Ku, M., Quach, H., Gasiorowski, R., Mulligan, S., Hamad, N., et al (2020). Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Internal Medicine Journal, 50(6), 667-679. [More Information]
Abadir, E., Gasiorowski, R., Silveira, P., Larsen, S., Clark, G. (2020). Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia? Journal of Clinical Medicine, 9(2), 1-15. [More Information]
Abadir, E., Silveira, P., Gasiorowski, R., Ramesh, M., Romano, A., Mekkawy, A., Lo, T., Kabani, K., Sutherland, S., Pietersz, G., Ho, P., Larsen, S., Clark, G., et al (2020). Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia. Blood Advances, 4(7), 1206-1216. [More Information]
Abadir, E., Gasiorowski, R., Lai, K., Kupresanin, F., Romano, A., Silveira, P., Lo, T., Fromm, P., Kennerson, M., Iland, H., Ho, P., Hart, D., Clark, G., et al (2019). CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation. Molecular Oncology, 13(10), 2107-2120. [More Information]
Tamilarasan, A., Katelaris, P., Gasiorowski, R., Liyanasuriya, R. (2019). Dasatinib-induced colitis: a case report. Pathology, 51(7), 757-759. [More Information]
Lo, T., Abadir, E., Gasiorowski, R., Kabani, K., Ramesh, M., Orellana, D., Fromm, P., Kupresanin, F., Newman, E., Cunningham, I., Hart, D., Silveira, P., Clark, G. (2019). Examination of CD302 as a potential therapeutic target for acute myeloid leukemia. PloS One, 14(5), 1-15. [More Information]
Wight, J., Yue, M., Keane, C., Johnston, A., Linton, K., Chin, C., Wai, S., Talaulikar, D., Gasiorowski, R., Cheah, C., et al (2019). Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. British Journal of Haematology, 187(2), 174-184. [More Information]
Othman, J., Verner, E., Tam, C., Huang, J., Lin, L., Hilger, J., Trotman, J., Gasiorowski, R. (2018). Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenstrom macroglobulinemia. Haematologica, 103(5), e223-e225. [More Information]
Trotman, J., Trinh, J., Kwan, Y., Estell, J., Fletcher, J., Archer, K., Lee, K., Foo, K., Curnow, J., Bianchi, A., Gasiorowski, R., Cunningham, I., et al (2017). Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice. Internal Medicine Journal, 47(5), 542-548. [More Information]
Clark, G., Kupresanin, F., Fromm, P., Ju, X., Muusers, L., Silveira, P., Elgundi, Z., Gasiorowski, R., Papadimitrious, M., Bryant, C., Lee, K., Harman, A., Hart, D., et al (2016). New insights into the phenotype of human dendritic cell populations. Clinical & Translational Immunology, 5(1), 1-12. [More Information]
Gasiorowski, R., Clark, G., Bradstock, K., Hart, D. (2014). Antibody therapy for acute myeloid leukaemia. British Journal of Haematology, 164(4), 481-495. [More Information]
Hocking, J., Schwarer, A., Gasiorowski, R., Patil, S., Avery, S., Gibson, J., Iland, H., Ho, P., Joshua, D., Muirhead, J., et al (2014). Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol. Leukemia & Lymphoma, 55(12), 2801-2807. [More Information]
Gasiorowski, R., Ju, X., Hart, D., Clark, G. (2013). CD300 molecule regulation of human dendritic cell functions. Immunology Letters, 149(1-2), 93-100. [More Information]

show 19 more

By Year

Expand all

2024

Thieblemont, C., Lewis, D., Kim, T., van der Poel, M., Poon, M., Feldman, T., Linton, K., Sureda, A., Hutchings, M., Dinh, M., Gasiorowski, R., et al (2024). Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. [More Information]

2023

Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C., Clausen, M., Cunningham, D., Do, Y., Feldman, T., Gasiorowski, R., Jurczak, W., et al (2023). Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. Journal of Clinical Oncology, 41(12), 2238-2247. [More Information]

2022

Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C., Clausen, M., Cunningham, D., Do, Y., Feldman, T., Gasiorowski, R., Jurczak, W., et al (2022). ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study. Clinical Lymphoma, Myeloma and Leukemia, 22, S379. [More Information]
Gasiorowski, R., Forbes, M., Silver, G., Krastev, Y., Hamdorf, B., Lewis, B., Tisbury, M., Cole-Sinclair, M., Lanphear, B., Klein, R., et al (2022). Effect of Plasma and Blood Donations on Levels of Perfluoroalkyl and Polyfluoroalkyl Substances in Firefighters in Australia: A Randomized Clinical Trial. JAMA Network Open, 5(4), E226257. [More Information]
Wong, J., Gruber, E., Maher, B., Waltham, M., Sabouri-Thompson, Z., Jong, I., Luong, Q., Levy, S., Kumar, B., Brasacchio, D., Gasiorowski, R., et al (2022). Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. Leukemia, 36(6), 1654-1665. [More Information]
Zinzani, P., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N., de Oliveira, J., Buccheri, V., Perini, G., Dickinson, M., et al (2022). Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Advances, 6(2), 590-599. [More Information]

show 1 more

2021

Morschhauser, F., Feugier, P., Flinn, I., Gasiorowski, R., Greil, R., Illés, Á., Johnson, N., Larouche, J., Lugtenburg, P., Patti, C., et al (2021). A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood, 137(5), 600-609. [More Information]
Kuruvilla, J., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N., Fogliatto, L., Goncalves, I., de Oliveira, J., Buccheri, V., et al (2021). Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. The Lancet Oncology, 22(4), 512-524. [More Information]
Silver, G., Krastev, Y., Forbes, M., Hamdorf, B., Lewis, B., Tisbury, M., Taylor, M., Gasiorowski, R. (2021). Study protocol for a randomised controlled trial examining the effect of blood and plasma donation on serum perfluoroalkyl and polyfluoroalkyl substance (PFAS) levels in firefighters. BMJ Open, 11(5), e044833. [More Information]

2020

Di Ciaccio, P., McCaughan, G., Trotman, J., Ho, P., Cheah, C., Gangatharan, S., Wight, J., Ku, M., Quach, H., Gasiorowski, R., Mulligan, S., Hamad, N., et al (2020). Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Internal Medicine Journal, 50(6), 667-679. [More Information]
Abadir, E., Gasiorowski, R., Silveira, P., Larsen, S., Clark, G. (2020). Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia? Journal of Clinical Medicine, 9(2), 1-15. [More Information]
Abadir, E., Silveira, P., Gasiorowski, R., Ramesh, M., Romano, A., Mekkawy, A., Lo, T., Kabani, K., Sutherland, S., Pietersz, G., Ho, P., Larsen, S., Clark, G., et al (2020). Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia. Blood Advances, 4(7), 1206-1216. [More Information]

2019

Abadir, E., Gasiorowski, R., Lai, K., Kupresanin, F., Romano, A., Silveira, P., Lo, T., Fromm, P., Kennerson, M., Iland, H., Ho, P., Hart, D., Clark, G., et al (2019). CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation. Molecular Oncology, 13(10), 2107-2120. [More Information]
Tamilarasan, A., Katelaris, P., Gasiorowski, R., Liyanasuriya, R. (2019). Dasatinib-induced colitis: a case report. Pathology, 51(7), 757-759. [More Information]
Lo, T., Abadir, E., Gasiorowski, R., Kabani, K., Ramesh, M., Orellana, D., Fromm, P., Kupresanin, F., Newman, E., Cunningham, I., Hart, D., Silveira, P., Clark, G. (2019). Examination of CD302 as a potential therapeutic target for acute myeloid leukemia. PloS One, 14(5), 1-15. [More Information]
Wight, J., Yue, M., Keane, C., Johnston, A., Linton, K., Chin, C., Wai, S., Talaulikar, D., Gasiorowski, R., Cheah, C., et al (2019). Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. British Journal of Haematology, 187(2), 174-184. [More Information]

show 1 more

2018

Othman, J., Verner, E., Tam, C., Huang, J., Lin, L., Hilger, J., Trotman, J., Gasiorowski, R. (2018). Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenstrom macroglobulinemia. Haematologica, 103(5), e223-e225. [More Information]

2017

Trotman, J., Trinh, J., Kwan, Y., Estell, J., Fletcher, J., Archer, K., Lee, K., Foo, K., Curnow, J., Bianchi, A., Gasiorowski, R., Cunningham, I., et al (2017). Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice. Internal Medicine Journal, 47(5), 542-548. [More Information]

2016

Clark, G., Kupresanin, F., Fromm, P., Ju, X., Muusers, L., Silveira, P., Elgundi, Z., Gasiorowski, R., Papadimitrious, M., Bryant, C., Lee, K., Harman, A., Hart, D., et al (2016). New insights into the phenotype of human dendritic cell populations. Clinical & Translational Immunology, 5(1), 1-12. [More Information]

2014

Gasiorowski, R., Clark, G., Bradstock, K., Hart, D. (2014). Antibody therapy for acute myeloid leukaemia. British Journal of Haematology, 164(4), 481-495. [More Information]
Hocking, J., Schwarer, A., Gasiorowski, R., Patil, S., Avery, S., Gibson, J., Iland, H., Ho, P., Joshua, D., Muirhead, J., et al (2014). Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol. Leukemia & Lymphoma, 55(12), 2801-2807. [More Information]

2013

Gasiorowski, R., Ju, X., Hart, D., Clark, G. (2013). CD300 molecule regulation of human dendritic cell functions. Immunology Letters, 149(1-2), 93-100. [More Information]

Faculty of Medicine and Health

Page not found

Dr Robin Gasiorowski

Publications

By Type

By Year